Swiss pharmaceutical giant Roche has signed a groundbreaking agreement with Danish biotech company Zealand Pharma, valued at up to $5.3 billion, to advance a promising obesity treatment drug. This partnership highlights Roche's ambition to fortify its stance in the swiftly growing market for weight-loss medications, dominated by industry leaders like Novo Nordisk and Eli Lilly.